LEO Pharma A/S - Product Pipeline Review - 2016

  • ID: 3746934
  • Company Profile
  • 49 pages
  • Global Markets Direct
  • LEO Laboratories Ltd.
1 of 4
LEO Pharma A/S - Product Pipeline Review - 2016

Summary

‘LEO Pharma A/S - Product Pipeline Review - 2016’, provides an overview of the LEO Pharma A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by LEO Pharma A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of LEO Pharma A/S
- The report provides overview of LEO Pharma A/S including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses LEO Pharma A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features LEO Pharma A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate LEO Pharma A/S’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for LEO Pharma A/S
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding LEO Pharma A/S’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

LEO Pharma A/S Snapshot

LEO Pharma A/S Overview

Key Information

Key Facts

LEO Pharma A/S - Research and Development Overview

Key Therapeutic Areas

LEO Pharma A/S - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

LEO Pharma A/S - Pipeline Products Glance

LEO Pharma A/S - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

LEO Pharma A/S - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

LEO Pharma A/S - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

LEO Pharma A/S - Drug Profiles

(betamethasone dipropionate + calcipotriene)

Product Description

Mechanism of Action

R&D Progress

LEO-43204

Product Description

Mechanism of Action

R&D Progress

aprepitant

Product Description

Mechanism of Action

R&D Progress

ingenol mebutate

Product Description

Mechanism of Action

R&D Progress

LEO-124249

Product Description

Mechanism of Action

R&D Progress

LP-0113

Product Description

Mechanism of Action

R&D Progress

LEO-130852A

Product Description

Mechanism of Action

R&D Progress

LEO-32731

Product Description

Mechanism of Action

R&D Progress

LEO-39652

Product Description

Mechanism of Action

R&D Progress

VBY-891

Product Description

Mechanism of Action

R&D Progress

LP-0067

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize MCHR1 for Weight Loss

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Activate Protein Kinase C for Dermatology and Oncology

Product Description

Mechanism of Action

R&D Progress

LEO Pharma A/S - Pipeline Analysis

LEO Pharma A/S - Pipeline Products by Target

LEO Pharma A/S - Pipeline Products by Route of Administration

LEO Pharma A/S - Pipeline Products by Molecule Type

LEO Pharma A/S - Pipeline Products by Mechanism of Action

LEO Pharma A/S - Recent Pipeline Updates

LEO Pharma A/S - Dormant Projects

LEO Pharma A/S - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

(calcipotriene + hydrocortisone butyrate)

TD-1414

LEO Pharma A/S - Company Statement

LEO Pharma A/S - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

LEO Pharma A/S, Key Information

LEO Pharma A/S, Key Facts

LEO Pharma A/S - Pipeline by Indication, 2016

LEO Pharma A/S - Pipeline by Stage of Development, 2016

LEO Pharma A/S - Monotherapy Products in Pipeline, 2016

LEO Pharma A/S - Combination Treatment Modalities in Pipeline, 2016

LEO Pharma A/S - Partnered Products in Pipeline, 2016

LEO Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2016

LEO Pharma A/S - Pre-Registration, 2016

LEO Pharma A/S - Phase III, 2016

LEO Pharma A/S - Phase II, 2016

LEO Pharma A/S - Phase I, 2016

LEO Pharma A/S - Preclinical, 2016

LEO Pharma A/S - Discovery, 2016

LEO Pharma A/S - Pipeline by Target, 2016

LEO Pharma A/S - Pipeline by Route of Administration, 2016

LEO Pharma A/S - Pipeline by Molecule Type, 2016

LEO Pharma A/S - Pipeline Products by Mechanism of Action, 2016

LEO Pharma A/S - Recent Pipeline Updates, 2016

LEO Pharma A/S - Dormant Developmental Projects,2016

LEO Pharma A/S - Discontinued Pipeline Products, 2016

LEO Pharma A/S, Subsidiaries

List of Figures

LEO Pharma A/S - Pipeline by Top 10 Indication, 2016

LEO Pharma A/S - Pipeline by Stage of Development, 2016

LEO Pharma A/S - Monotherapy Products in Pipeline, 2016

LEO Pharma A/S - Partnered Products in Pipeline, 2016

LEO Pharma A/S - Pipeline by Top 10 Target, 2016

LEO Pharma A/S - Pipeline by Route of Administration, 2016

LEO Pharma A/S - Pipeline by Molecule Type, 2016

LEO Pharma A/S - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll